drugset
Drugs / SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant
last change Jan 2022 re-read 3 minutes ago

SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant

Vaccine

Developed for
COVID-19
Investigated by
Ihsan GURSEL, PhD, Prof. · MonitorCRO · Nobel Pharmaceuticals · The Scientific and Technological Research Council of Turkey

Trials 1

today NCT04962893 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04962893 Jun 2021 → Jan 2022 COVID-19 Ihsan GURSEL, PhD, Prof. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant ClinicalTrials.gov intervention name — accepted as the source's own label NCT04962893 ↗
Modality Vaccine “VLP vaccine” NCT04962893 ↗
Route Subcutaneous “All injections will be done subcutaneously.” NCT04962893 ↗